Ionis pharmaceuticals, inc. (IONS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10
Operating activities:
Net income (loss)

153,898

303,262

402,036

363,239

316,681

214,985

-96,914

-84,042

-30,559

-10,783

50,405

65,250

11,481

-60,400

-183,854

-226,981

-134,478

-88,278

14,208

23,308

-24,421

-38,984

-94,313

-92,207

-90,252

-60,644

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Depreciation

12,700

12,540

12,401

12,101

11,416

10,706

8,220

7,576

7,091

6,708

8,027

7,756

7,620

7,481

7,386

7,293

7,254

6,984

6,779

6,645

6,390

6,380

6,387

6,357

6,445

6,591

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amount of amortization expense attributable to right-of-use asset from operating lease.

1,459

1,542

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of patents

1,928

1,912

1,605

1,875

1,849

1,822

1,781

1,734

1,691

1,641

1,597

1,579

1,568

1,552

1,540

1,508

1,446

1,381

1,313

1,247

1,191

1,142

1,134

1,143

1,162

1,184

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of licenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,873

1,875

1,878

1,880

1,882

1,888

1,897

1,909

2,007

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premium (discount) on investments, net

3,990

7,485

8,868

8,021

4,638

1,013

-2,316

-5,039

-6,336

-6,752

-6,726

-6,578

-6,382

-6,813

-7,631

-8,228

-8,102

-7,812

-7,316

-7,000

-7,843

-7,470

-7,479

-7,037

-5,840

-5,572

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

2,063

1,942

1,915

1,914

1,843

1,810

1,757

1,672

1,661

1,616

1,517

1,421

1,323

1,225

1,202

1,179

1,156

1,133

1,024

878

735

595

519

485

450

415

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of convertible senior notes discount

37,446

37,338

35,329

34,660

34,006

33,363

32,738

32,121

31,497

30,920

29,115

27,344

25,601

23,890

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of long-term financing liability for leased facility

-

-

-

-

-

-

-

-

-

3,659

5,334

6,700

6,696

6,693

6,689

6,683

6,675

6,665

6,654

6,643

6,632

6,622

6,610

6,597

6,582

6,567

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of 2 3/4 percent convertible senior notes discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

141,859

146,574

145,666

156,422

148,366

131,312

119,543

106,132

93,514

85,975

78,800

74,914

72,917

72,108

74,357

71,768

66,112

59,314

50,396

43,516

37,619

31,383

25,994

20,690

15,618

11,418

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Gain on investment in Regulus Therapeutics, Inc.

-

-

-

-

-

-

-

-

-

374

374

374

374

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill and an other than temporary decline in value that has been recognized against investments accounted for under the cost method of accounting.

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on investments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,256

445

617

1,717

2,378

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash losses related to patents, licensing and property, plant and equipment

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

2,184

-

2,302

1,796

1,506

1,305

5,982

6,244

6,292

6,306

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Provision for deferred income taxes

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tax benefit from other unrealized gains on securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,357

-12,835

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Contracts receivable

18,153

47,674

34,344

14,853

-26,406

-47,595

-28,192

-33,853

-32,499

-45,088

34,380

49,869

52,877

96,687

6,718

-2,518

-10,454

7,453

-24,487

-38,677

17,111

-7,199

13,668

39,917

8,651

10,580

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

5,117

5,411

6,810

5,251

1,997

-1,400

-73

2,563

2,259

2,493

-868

-1,164

281

590

2,736

886

-319

609

-502

-994

-698

-1,743

-300

-533

1,728

1,912

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Other current and long-term assets

36,453

44,659

26,152

30,543

39,444

29,348

50,074

24,173

32,868

58,367

33,237

35,192

9,727

-1,603

-9,037

-7,659

4,690

4,394

13,968

15,684

3,305

1,750

795

1,294

386

1,091

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

1,259

-16,343

-5,813

-2,520

-4,702

-655

-10,115

-2,425

-11,832

1,784

2,816

-8,271

1,212

-10,677

-6,851

4,972

489

9,211

4,272

-5,364

4,775

4,824

3,773

3,890

2,989

66

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

173

8,089

145

4,960

4,098

4,117

9,072

4,791

3,899

965

4,179

2,857

1,930

8,121

1,500

-474

926

3,763

2,344

1,485

1,083

134

511

-601

510

4,290

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Other current liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

251

190

153

170

188

202

217

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-305

-989

8,358

13,294

8,791

6,979

6,691

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and deferred liabilities due within one year or operating cycle.

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred contract revenue

-98,609

-119,283

-49,943

-63,203

481,689

494,254

446,279

458,408

-73,541

30,182

-10,977

1,001

5,478

-85,306

-58,866

4,496

15,110

22,118

54,895

-5,534

-13,514

-11,415

-44,642

56,354

91,123

88,344

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

230,431

345,720

183,278

170,080

697,428

602,888

507,799

562,523

64,649

174,149

126,909

122,475

86,328

-112,105

-122,740

-110,808

-11,817

21,125

129,283

95,009

-4,213

6,285

-78,891

-15,014

41,741

63,493

114,020

23,328

-1,989

1,876

-56,900

-55,198

-78,798

-111,929

-114,691

-112,951

-81,744

-63,593

0

0

0

Investing activities:
Purchases of short-term investments

1,998,320

1,946,726

2,256,126

2,195,107

2,196,359

1,794,735

1,444,490

1,178,796

702,782

877,810

656,081

567,014

525,731

300,912

329,877

334,711

494,620

493,467

539,379

453,257

362,911

391,883

372,272

460,500

430,187

425,554

349,158

245,474

220,588

217,877

259,310

279,038

322,785

371,108

384,885

412,697

514,703

530,137

0

0

0

Proceeds from sale of short-term investments

1,984,218

1,951,734

1,779,907

1,396,742

1,135,968

882,824

812,026

718,942

631,870

557,369

400,461

386,889

381,990

364,572

404,446

412,220

422,929

419,584

364,940

306,472

277,899

294,727

260,528

251,613

218,974

172,762

188,392

196,904

229,954

242,659

306,443

333,422

380,371

488,918

465,929

573,437

589,240

577,533

0

0

0

Purchases of property, plant and equipment

36,756

30,905

24,530

11,874

14,494

13,608

20,483

34,288

33,870

34,764

29,296

13,297

9,716

7,107

6,724

7,015

7,442

7,692

8,830

8,358

6,993

7,518

4,408

4,061

2,733

1,552

1,559

1,206

1,588

1,479

2,302

5,085

7,740

10,203

9,431

7,325

4,804

13,237

0

0

0

Proceeds from land sold to BioMed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,147

0

0

0

Reduction of cash due to deconsolidation of Regulus Therapeutics Inc. upon adoption of a new accounting standard

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,228

0

0

0

The cash outflow for acquisition of licenses and other assets not otherwise defined in the taxonomy.

5,249

5,377

4,923

4,500

4,338

4,044

2,121

3,354

2,848

3,093

5,336

3,819

5,022

4,421

4,096

4,502

3,719

4,056

4,477

3,544

3,972

3,586

3,532

4,430

3,441

3,810

3,633

3,270

4,044

3,691

3,902

3,504

3,505

3,667

3,433

3,619

4,314

4,319

0

0

0

Proceeds from the sale of Regulus Therapeutics, Inc.

-

-

-

-

-

-

-

-

-

2,507

6,974

6,974

6,974

4,467

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-66,107

-41,274

-505,672

-814,739

-1,079,223

-929,563

-657,568

-499,996

-110,130

-358,291

-283,278

-190,267

-151,505

56,599

63,762

91,571

-57,273

-60,052

-138,804

-134,012

-71,019

-82,848

-117,330

-216,151

-215,599

-255,726

-165,421

-52,721

3,215

17,999

45,334

50,240

50,786

108,026

68,414

150,030

65,454

23,694

0

0

0

Financing activities:
Proceeds from issuance of equity, net

60,252

119,657

121,783

119,726

89,282

27,900

23,513

23,182

22,282

22,931

23,835

19,224

17,005

13,417

11,867

10,973

13,508

24,888

0

0

0

-

23,769

39,495

63,138

62,958

58,579

44,732

20,655

9,470

9,802

4,308

3,522

3,567

3,874

3,950

4,008

4,356

0

0

0

Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options

23,248

19,242

18,841

8,034

7,597

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of strategic investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

359

-49

-49

150

250

0

0

0

Proceeds from the sale of strategic investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,463

2,354

1,227

1,788

2,428

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases and retirements of common stock

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on debt and capital lease obligations

-

-

-

-

-

-

-

-

-

3,599

5,215

6,627

6,849

7,066

7,223

7,585

8,325

9,058

9,847

10,385

10,486

10,587

10,736

10,858

10,957

11,039

11,146

11,159

10,701

10,419

9,007

7,827

6,944

5,864

5,692

5,281

4,802

4,354

0

0

0

Proceeds from the issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

71,640

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs paid

-

-

-

-

-

-

-

-

1,710

2,037

995

1,849

1,596

818

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-53,940

100,021

90,442

111,692

530,101

475,865

470,476

609,972

158,765

229,087

231,278

88,249

86,061

11,394

16,660

12,284

14,079

24,726

62,894

64,409

61,802

59,588

13,033

28,706

227,986

227,724

223,246

240,288

50,033

39,130

40,866

5,581

-1,797

-672

1,418

1,905

3,900

4,696

0

0

0

Net increase in cash and cash equivalents

110,384

404,467

-231,952

-532,967

148,306

149,190

320,707

672,499

113,284

44,945

74,909

20,457

20,884

-44,112

-42,318

-6,953

-55,011

-14,201

53,373

25,406

-13,430

-16,975

-183,188

-202,459

54,128

35,491

171,845

210,895

51,259

59,005

29,300

623

-29,809

-4,575

-44,859

38,984

-12,390

-35,203

0

0

0

Supplemental disclosures of cash flow information:
Interest paid

9,804

9,870

9,632

9,615

9,615

9,592

9,449

9,181

8,573

8,035

7,038

7,506

7,388

7,313

6,862

6,837

6,794

6,800

7,609

6,810

6,307

6,353

5,898

5,943

5,970

6,000

3,265

6,472

3,672

5,770

5,741

4,681

4,740

4,804

4,842

4,874

4,883

4,889

0

0

0

Income taxes paid

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

2

-428

-428

-428

7,270

0

0

0

Supplemental disclosures of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities

621

14,178

14,178

13,920

13,557

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Future cash outflow to pay for purchases of fixed assets and patents that have been incurred.

6,165

3,126

5,383

4,856

4,201

4,428

804

2,923

2,426

1,983

4,393

3,482

2,563

3,439

3,236

1,658

2,488

1,162

-606

2,864

1,843

2,151

3,073

102

1,495

704

643

1,023

518

647

363

501

524

902

1,373

1,171

1,308

922

0

0

0

Future cash outflow to pay for deferred offering costs attributable to an offering of securities that have been incurred.

-

-

-

-

-

-

-

-

-

-

878

385

610

291

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-